Recently reported positive preliminary data from Phase 1 dose escalation trial of micvotabart pelidotin ("MICVO," formerly PYX-201), including a confirmed 50% objective response rate by RECIST 1.1 ...

Certain categories will now earn fewer rewards points than before, such as online spending on Swiggy and purchases of Air India tickets. Here's a detailed breakdown of the modifications.